Journal article
Patient-derived xenograft establishment from human malignant pleural mesothelioma
L Wu, G Allo, T John, M Li, T Tagawa, I Opitz, M Anraku, Z Yun, M Pintilie, B Pitcher, G Liu, R Feld, MR Johnston, M De Perrot, MS Tsao
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2017
Abstract
Purpose: Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with few therapeutic options. The tumor-stromal interface is important in MPM, but this is lost in cell lines, the main model used for preclinical studies. We sought to characterize MPM patient-derived xenografts (PDX) to determine their suitability as preclinical models and whether tumors that engraft reflect a more aggressive biological phenotype. Experimental Design: Fresh tumors were harvested from extrapleural pneumonectomy, decortication, or biopsy samples of 50 MPM patients and implanted subcutaneously into immunodeficient mice and serially passaged for up to five generations. We correlated selected mesothe..
View full abstractGrants
Awarded by Ontario Ministry of Health and Long-Term Care
Funding Acknowledgements
This work was partially supported by research grants from Lilly Canada and the Imperial Oil of Canada. G. Allo was supported by the Terry Fox Foundation Training Program in Molecular Pathology of Cancer at CIHR (STP 53912). M.-S. Tsao is the M. Qasim Choksi Chair in Lung Cancer Translational Research. G. Liu is the Alan B. Brown Chair in Molecular Genomics. M. de Perrot is the Director of Toronto Mesothelioma Research Program. The study is partially supported by the Ontario Ministry of Health and Long Term Care (OMHLTC) and Ontario Institute for Cancer.